Merck & Company
West Coast Innovation Hub
499 Illinois St. Suite 100
About Merck & Company
Merck and Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures, and markets vaccines and medicines in over 20 therapeutic categories directly and through its joint ventures. Our mission is to provide society with superior products and services by developing innovations and solutions that improve the quality of life. The focus of research at Merck is on innovation in all areas of drug research and development, working on programs to satisfy unmet medical needs.
With approximately 60,000 employees, Merck conducts research at ten major research centers in the United States, Europe, and Japan, manufactures products in 30 facilities, and sells products in approximately 150 countries.
At Merck, our strategy for growth is based on breakthrough research - both internal and external through partnerships - and demonstrating the value of our medicines to patients, payers, and providers. Worldwide sales in 2004 were $22.9 billion. Merck continues to invest heavily in research and development, with R&D spending in 2005 estimated to be approximately $4 billion.
Merck's product line includes a broad portfolio of highly innovative prescription products in important therapeutic areas. Human health products include medicines to treat high blood pressure, congestive heart failure, elevated cholesterol levels, osteoporosis, benign prostatic hypertrophy, arthritis, pain, migraine, glaucoma, gastrointestinal ulcers, infectious diseases (antibiotic, anti-fungal, and antiviral agents), and vaccines to prevent childhood diseases and hepatitis A and B.
At Merck, we are strongly committed to partnership success. We have a long tradition of successful partnerships. Alliances with innovative partners are an integral part of our long-term business and research strategy. More than one-third of our sales are from alliance products and patents, including some of our biggest growth drivers.
Our vision is to create a "virtual lab" - the pursuit of the best scientific programs from both internal research and external collaborations. This approach will accelerate the successful development and commercialization of breakthrough discoveries that can bring meaningful improvements to patients' lives.
Our focus is seeking alliances for new NCE's and biological entities as product candidates for development. We are open to basic research collaborations and early research technologies as well.
Merck welcomes partnerships touching virtually all human health therapeutic areas that address unmet needs for patients, as well as technologies that will enhance the productivity of our research laboratories. Therapeutic areas of particular interest include cancer, central nervous system disorders, diabetes, and obesity. Also of interest include the following: anti-infectives, anti-virals, cardiovascular diseases, gastrointestinal diseases, immunology, new vaccine technology, ophthalmics, osteoporosis, pain, respiratory, vaccines, and platform research technology.
To contact Merck about a licensing opportunity, please contact Chief Licensing Officer, Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889 USA; Fax: 908-735-1201. Please provide a brief, non-confidential overview of your discovery with sufficient data to allow a preliminary scientific review.
For further information, please visit our website at http://www.merck.com/licensing/
73 articles with Merck & Company
Zymeworks Inc. announced that it has earned a milestone payment from Merck achieved under the companies’ 2014 research and license agreement.
U.S. Senator Chuck Grassley (R-Iowa) set the tone early, mentioning his constituents rationing drugs because of high prices or “leaving their prescription on the pharmacy counter because it costs too much,” but acknowledging that innovations “take time and money.”
KEYTRUDA® (pembrolizumab) Monotherapy Significantly Improved Overall Survival in KEYNOTE-042 Study as First-Line Treatment for Locally Advanced or Metastatic NSCLC Patients Whose Tumors Expressed PD-L1 (TPS ≥1%)
Merck announced results from KEYNOTE-042, a pivotal, Phase 3 study evaluating KEYTRUDA
Rounding out the top five companies behind J&J and Sanofi are AbbVie, Celgene and Merck.
Merck & Co., Inc. (San Francisco) (JOBS) CEO Announces Structure and Global Leadership Team for New Merck; Company to Form 5 Divisions After Schering-Plough Corporation (JOBS) Buyout
Merck & Co., Inc. (JOBS) Wins SINGULAIR(R) Patent Infringement Lawsuit TEVA Pharmaceuticals USA (JOBS)
Covance Inc. (JOBS) and Merck & Co., Inc. (JOBS) Finalize Strategic Agreement for $145 Million Contract; Covance to Acquire Merck's Seattle-Based Gene Expression Laboratory
Merck & Co., Inc. (JOBS), Schering-Plough Corporation (JOBS) in $41.5 Million Cholesterol Settlement
Covance Inc. (JOBS) to Acquire Seattle-Based Gene Expression Laboratory from Merck & Co., Inc. (JOBS); Five-Year $145 Million Contract
Sanofi-Aventis (France) to Buy Merial (JOBS) Stake from Merck & Co., Inc. (JOBS) According to Source
Cardiome Pharma Corp. Achieves $15 Million Milestone From Collaboration With Merck & Co., Inc. (JOBS)
MicroDose Therapeutx (formerly MicroDose Technologies Inc) Announces Expansion of Collaboration with Merck & Co., Inc. for Dry Powder Inhaler Technology
Depomed, Inc. (JOBS) Provides License for Patents Covering Metformin Extended Release Technology to Merck & Co., Inc. (JOBS); Depomed to Receive $10 Million Upfront Fee